ATS 2021, News
Patients with normal adrenal function are largely able to eliminate the use of oral corticosteroids or achieve a daily dose of 5 mg or less.
Highest rates of adverse events seen within first month after initiating short course of oral steroids.
Drugs in the Pipeline
Findings from a phase 3b trial showed that a majority of patients with severe eosinophilic asthma treated with benralizumab (Fasenra; AstraZeneca), an interleukin-5 antagonist, were able to eliminate or reduce oral corticosteroid (OCS) use. The open-label, single-arm PONENTE trial assessed the efficacy and safety of reducing OCS use after initiating treatment with benralizumab in nearly…
TRAVERSE trial findings on the efficacy, safety, and OCS-sparring effect of dupilumab for severe OCS-dependent asthma were presented at ATS 2022.
AAAAI 2021, News
Patients with asthma who depend on oral corticosteroids (OCS) may be able to reduce the dependence or eliminate the use of OCS altogether with benralizumab.
CHEST 2021, News
A post-hoc analysis of the VENTURE trial evaluated whether baseline oral corticosteroid dosage affected the efficacy of dupilumab in improving severe asthma outcomes.
ATS 2021, News
Long-term treatment of oral corticosteroid (OCS)-dependent asthma with dupilumab has shown efficacy in weaning off OCS while improving lung function.
Oral, inhaled corticosteroid use linked to increased risk for osteoporosis, fragility fractures
Zolgensma is an adeno-associated virus vector-based gene therapy.